Turn Your Brick-Dust API into an Effective Parenteral Treatment with Apisolex™ Polymer

LUBRIZOL LIFE SCIENCE



1 From Brick-Dust to Effective Drug Product

Even in the final stages of development, many promising APIs fail due to poor physicochemical properties.

Poor aqueous solubility and bioavailability are common challenges in drug development, making many promising drugs impossible to formulate.

Finding scalable approaches to solve these issues is critical to achieve clinical efficacy and to expedite a new drug or 505(b)(2) to market.

90%

Up to 90% of new chemical entities (NCEs) suffer from poor aqueous solubility.



2 Nanoencapsulate your Brick-Dust API with Apisolex™ Polymer

Lubrizol Life Science (LLS) Health's Apisolex polymer is the newest addition to its excipient family. By adding solubility enhancing polymers, we're adapting to market needs and continuing our legacy of over 40-years experience in creating innovative, reliable, and differentiated solutions.

Apisolex excipient's robust IP estate provides a powerful tool for drug formulators to unlock the potential of brick-dust APIs and get parenteral drug formulations to market.

x50K

Apisolex technology increases the solubility of hydrophobic APIs by up to 50,000-fold, for both amorphous and crystalline APIs.



3 Solving Solubility Issues with Apisolex Polymer

Apisolex excipient's polyamino acid structure provides a non-toxic, non-immunogenic, and biocompatible alternative to traditional PEG-based excipients.

Designed to work with straight-forward formulation techniques, Apisolex technology provides many benefits, including:

- High drug loading, up to 40%
- Minimal API loss
- Stable, lyophilized drug products
- Saline reconstitution in <30 seconds

Did you know?

The maximum tolerated dose of many oncology drug products is limited not only by API toxicity, but also by the toxicity of the vehicle and/or excipients.



4 Add Value with Apisolex Polymers for Patient-Centric Treatments

As the fight against cancer and orphan diseases continues, many promising APIs are being funded, developed, improved, or repurposed. To ensure vital yet insoluble drugs can be administered to patients, solutions such as Apisolex excipients are integral to realize their full therapeutic potential.

Apisolex polymers provide a simplified nanoparticle manufacturing technique that results in better drug products for patients.

Visit Apisolex.com to discover how Apisolex technology can help you overcome solubility issues.

The information contained herein is believed to be reliable, but no representations, guarantees or warranties of any kind are made as to its accuracy, suitability for particular applications or the results to be obtained. The information often is based on laboratory work with small-scale equipment and does not necessarily indicate end-product performance or reproducibility. Formulations presented may not have been tested for stability and should be used only as a suggested starting point. Because of the variations in methods, conditions and equipment used commercially in processing these materials, no warranties or guarantees are made as to the suitability of the products for the applications disclosed. Full-scale testing and end-product performance are the responsibility of the user. Lubrizol Advanced Materials, Inc., shall not be liable for and the customer assumes all risk and liability for any use or handling of any material beyond Lubrizol Advanced Materials, Inc.'s direct control. The SELLER MAKES NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. Nothing contained herein is to be considered as permission, recommendation nor as an inducement to practice any patented invention without permission of the patent owner. Lubrizol Advanced Materials, Inc., is a wholly owned subsidiary of The Lubrizol Corporation. - ©2022 The Lubrizol Corporation, all rights reserved. All marks are the property of The Lubrizol Corporation. The Lubrizol Corporation is a Berkshire Hathaway company.

22-0118344